GrantSet

Grant opportunity · PAR-25-180

First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)

Applications close442 days leftOct 15, 2027
AgencyNational Institutes of Health
CategoryDiscretionary
Assistance listing93.242
OpensNov 26, 2024
ClosesOct 15, 2027
Award floor
Award ceiling
Expected awardsNot stated

Who can apply (as listed)

  • County governments
  • Private institutions of higher education
  • City or township governments
  • State governments
  • Native American tribal organizations (other than federally recognized governments)
  • Nonprofits with 501(c)(3) status (other than institutions of higher education)
  • Public housing authorities / Indian housing authorities
  • Native American tribal governments (federally recognized)
  • Others (see the opportunity text)
  • Special district governments
  • Independent school districts
  • Public and state-controlled institutions of higher education
  • Small businesses
  • Nonprofits without 501(c)(3) status (other than institutions of higher education)
  • For-profit organizations (other than small businesses)
From the listing

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs, or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The NOFO will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase II studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The NOFO also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid col…

Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.

GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.